SABS News and Press, SAB Biotherapeutics Inc.

SAB Biotherapeutics, Inc. (NASDAQ: SABS) is one of today's top gainers. The company's shares have moved 0% on the day to $2.77. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advance...

2024-06-20 09:24:26 ET More on SAB Biotherapeutics: Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics Read the full article on Seeking Alpha For fu...

New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB&#...

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progre...

2024-05-30 16:48:49 ET More on SAB Biotherapeutics Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics Read the full article on Seeking Alpha For fur...

MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progres...

2024-05-21 10:00:13 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

2024-05-21 09:42:01 ET More on SAB Biotherapeutics Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics Read the full article on Seeking Alpha For fur...

MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the Company’s investigational new drug (IND) application to proc...

MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying th...